The neuropathological features of schizophrenia are suggestive of a developmentally induced impairment of synaptic connectivity. Semaphorin 3A (sema3A) might contribute to this process because it is a secreted chemorepellant which regulates axonal guidance. We have investigated sema3A in the cerebellum (an area in which expression persists in adulthood), and measured its abundance in 16 patients with schizophrenia and 16 controls. In adults, sema3A was predominantly localized to the inner part of the molecular layer neuropil, whereas infants and rats showed greater labelling of Purkinje cell bodies. Sema3A was increased in schizophrenia, as shown by enzyme-linked immunosorbent assay ( þ 28%; Po0.05) and immunohistochemistry ( þ 45%; Po0.01). We also measured reelin mRNA, since reelin is involved in related developmental processes and is decreased in other brain regions in schizophrenia. Reelin mRNA showed a trend reduction in the subjects with schizophrenia (À26%; P ¼ 0.07) and, notably, was negatively correlated with sema3A. Sema3A also correlated negatively with synaptophysin and complexin II mRNAs. The results show that sema3A is elevated in schizophrenia, and is associated with downregulation of genes involved in synaptic formation and maintenance. In this respect, sema3A appears to contribute to the synaptic pathology of schizophrenia, perhaps via ongoing effects of persistent sema3A elevation on synaptic plasticity. The findings are consistent with an early neurodevelopmental origin for the disorder, and the reciprocal changes in sema3A and reelin may be indicative of a pathogenic mechanism that affects the balance between trophic and inhibitory factors regulating synaptogenesis.
Introduction
Synaptic pathology is a feature of schizophrenia, detectable in terms of altered expression of synaptic proteins and as dendritic abnormalities. [1] [2] [3] It may be a manifestation of the aberrant neurodevelopment postulated to underlie the disorder. [4] [5] [6] The discovery of genes involved in key developmental processes, such as neuronal migration, axon guidance, and synaptogenesis, allows this hypothesis to begin to be molecularly tested. [7] [8] [9] [10] The semaphorins are signalling proteins involved in axon guidance 11 which share a stretch of B500 amino-terminal amino acids containing 17 conserved serine residues. Among the eight semaphorin classes, a key member is semaphorin 3A (sema3A, also called collapsin-1 or sema D). 12 Sema3A is a secreted axonal chemorepellant and thereby a determinant of the balance of synaptic inputs to particular cell types. [13] [14] [15] [16] [17] It is also involved in dendritic attraction 18, 19 and perhaps apoptosis. 20, 21 In this study, we have examined sema3A in schizophrenia as a contribution to the investigation of putative aberrant neurodevelopmental pathology in the disorder. The cerebellum was chosen for three reasons. First, because it is one of the few human brain regions in which sema3A expression persists at significant levels into adulthood. 22 Second, it is a node in a circuit proposed to be of central importance in schizophrenia. 23 Third, cerebellar synaptophysin and complexin II mRNAs are decreased in schizophrenia in this brain series; 24 given the inhibitory role of sema3A in axon guidance, we hypothesized an inverse relationship with the local expression of these presynaptic marker genes.
Reelin is another key neurodevelopmental molecule, with pleiotropic roles in regulation of axonal branching, synaptogenesis, and dendritic spine plasticity. [25] [26] [27] . Reelin is a serine protease, 28 and, like sema3A, is a secreted protein. In contrast to the inhibitory functions of sema3A, reelin has primarily attractant or trophic roles. In schizophrenia, reelin mRNA is decreased in the cerebellum and other regions. 29, 30 Hence, to complement the sema3A measurements, we also examined cerebellar reelin expression.
Methods and materials

Subjects studied
For the main sema3A study, tissue blocks were taken from the lateral cerebellar cortex (ansiform lobule) 31 of 16 subjects with schizophrenia and 16 controls ( Table 1) . Blocks were coded and stored at À701C. Schizophrenia was diagnosed by DSM-IIIR criteria. All patients had been treated with typical antipsychotics, and were on medication at the time of death. Further clinical information was available for 13 of the subjects: four had been long-term inpatients, six had active positive symptoms, five had persistent negative symptoms, and six were in remission. One patient had a history of alcohol abuse. Controls had no psychiatric or neurological history. All subjects died by natural causes, mostly myocardial infarction or bronchopneumonia. All brains were formally examined by a neuropathologist, using Nissl, silver and myelin stains, and had no neurodegenerative or focal lesions in excess of normal age-related changes. For the reelin study, tissue from two control subjects was unavailable, and was replaced by tissue from three demographically comparable individuals.
In addition, we examined sema3A in frozen sections from the cerebellum of four infants (two of each sex, aged 3.5-6 months, pH 6.35-6.74, postmortem interval (PMI)18.5-38 h) taken from the series described by Romanczk et al, 32 and from adult rats with simulated PMIs ranging from 0 to 72 h. This material together allowed us to address possible ontogenic, species, and PMI-associated effects on sema3A detection.
Western blotting
Western blotting was used to help validate the use of the anti-sema3A antibody in the human brain. Immediately before electrophoresis, 50 mg aliquots of protein extracts from whole fetal brain and adult cerebellum (Clontech, Basingstoke, UK) were mixed with an equal volume of 2 Â sodium dodecyl sulphate (SDS) gel-loading buffer (100 mM Tris HCl pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and boiled for 10 min. Samples were fractionated on an 8% polyacrylamide gel and transferred to Immobilon-P polyvinyl difluoride membranes (Millipore, Watford, UK) using a TransBlot electrophoresis transfer cell (BioRad, Hemel Hempstead, UK). After blocking nonspecific binding sites for 30 min with 5% bovine serum albumin in phosphate-buffered saline (PBS) containing 0.3% Triton XÀ100 (PBS-T), blots were incubated for 1 h at room temperature with a goat polyclonal antibody directed against a carboxy-terminal epitope of sema3A (amino acids 755-771) conserved between human and rat (SC-1146; Autogene Bioclear, Calne, UK) diluted 1:100 with PBS-T. Membranes were given 3 Â 5 min washes in PBS-T and then incubated with biotinylated rabbit anti-goat antibody (Sigma, Poole, UK) diluted 1:10 000 for 30 min and avidin-biotin conjugate (ABC) diluted 1:2500 for 30 min, the ABC coming from a Vector Elite ABC kit (Vector Laboratories, Peterborough, UK). After three final 5 min washes in PBS-T, western blots were detected by chemiluminescence using an ECL Plus kit (Amersham Pharmacia Biotech, Little Chalfont, UK) and exposed to Kodak X-OMAT-AR film (Amersham Pharmacia Biotech) for 30 s. Controls included omission of the primary antibody, and preincubation of the primary antibody overnight with the blocking peptide (SC-1146P) at the same concentration.
Enzyme-linked immunosorbent assay (ELISA)
Following pilot experiments to optimize sensitivity and establish the linear range for sema3A detection, ELISA was carried out using 0.5 mg tissue homogenate aliquots, spotted in triplicate upon Greiner Microlon Immunoassay plates (Jencons-PLS, Leighton Buzzard, UK). Nonspecific binding sites were blocked for 1 h with 10% normal rabbit serum. Plates were incubated overnight at 41C with the anti-sema3A antibody at 1:100. After three 1 min washes, plates were incubated for 1 h with a horseradish peroxidase-linked rabbit anti-goat antibody (1:2000, BioRad, Hemel Hempstead, UK), developed using a horseradish peroxidase substrate kit (BioRad), and read at 415 nm. Readings were corrected for nonspecific signal, defined by aliquots incubated concurrently but with omission of the primary antibody.
Immunohistochemistry
Frozen sections (18 mm) were fixed in 4% paraformaldehyde for 5 min, followed by a 30 min incubation in 3% hydrogen peroxide in methanol. After three brief washes in PBS, nonspecific binding sites were blocked with 10% normal rabbit serum in PBS-T for 30 min. Sections were incubated overnight at 41C with the anti-sema3A antibody, diluted 1:100 with PBS-T containing 1% normal rabbit serum and visualized using biotinylated rabbit anti-goat antibody (1:500, Sigma, Poole, UK) with an ABC Elite kit (Vector Laboratories) and diaminobenzidine. All subjects were included in a single experimental run, with three adjacent sections per case. Sema3A immunoreactivity was measured using KS400.3 image analysis software (Imaging Associates, Thame, UK). Given the distribution of sema3A immunoreactivity (see the Results section), signal was quantified in two ways. For the primary analysis, optical density measurements were taken over the sema3A immunoreactive band, with an average of 30 strips measured for each subject. For each section, the background signal (measured over the nonimmunoreactive portion of the molecular layer) was subtracted. As a secondary form of analysis, sema3A immunoreactivity was also quantified in terms of the percentage area labelled. For these measurements, a measuring box was placed over the sema3A immunoreactive band, and a binary image was produced after manual thresholding to remove background and leave only the immunoreactive structures highlighted. All analyses were done blind to group status.
In situ hybridization for reelin mRNA Reelin expression was assessed using in situ hybridization (ISH) to detect the encoding mRNA. ISH was carried out with a 36-base oligonucleotide probe, complementary to bases 1421-1457 of human reelin mRNA (accession number XM 004972), using methods described previously. 24, 33 Briefly, the probe was 3 0 -labelled with[a- 35 S]dATP (B1200 Ci/mmol, PerkinElmer Life Sciences, Hounslow, UK) at a 1:10 ratio using terminal deoxynucleotide transferase and labelling buffer (Promega, Southampton, UK) and purified using Sephadex G-50 columns (Amersham Pharmacia Biotech). Sections were incubated overnight at 311C in hybridization buffer containing 1 Â 10 6 counts per minute of purified labelled probe, and 50 mM dithiothreitol. Posthybridization washes were carried out in 1 Â standard saline citrate for 3 Â 20 min at 551C followed by 2 Â 60 min washes at room temperature. Hybridized sections were placed against Kodak Biomax MR film (Amersham Pharmacia Biotech) alongside 14 C microscales (Amersham Pharmacia Biotech) for 4 days. Experimental controls comprised hybridization with the sense orientation probe, and ribonuclease-treated sections. Triplicate adjacent sections from all subjects were incubated concurrently. Densitometry was carried out over the granule cell layer, with values being corrected for nonspecific signal as represented by sense strand hybridization.
Statistical analysis
Group differences were investigated using ANOVA, with age, pH, and PMI as covariates. Correlations between variables were investigated using the Pearson coefficient or partial correlations. All data were normally distributed, and there were no outliers. Significance was set at a ¼ 0.05, two-tailed.
Results
Detection and distribution of sema3A
Western blots probed with the SC-1146 anti-sema3A antibody showed a band at B40 kDa for adult cerebellum ( Figure 1a ) and B50 kDa for fetal brain (Figure 1b) , with no band seen after preadsorption with the blocking peptide (not shown). Specificity of the antibody for sema3A in the tissue sections was confirmed by (1) the absence of immunoreactivity after omission of the primary antibody, and (2) an identical distribution of staining seen, in human and rat cerebellum, with another antibody directed against a different region of sema3A (SC-1148; Autogene Bioclear; data not shown).
Sema3A in the adult human cerebellum was concentrated in the inner part of the molecular layer, adjacent to and just above the Purkinje cells ( Figure  2a) . The immunostaining took the form of small, discrete patches of immunoreactivity, located in the neuropil, together with weak staining of some Purkinje cell bodies. There was no significant labelling noted in other layers of the cerebellar cortex, nor over other cell types. The infant human (Figure 2b ) and rat (Figure 2c ) cerebellum showed stronger Purkinje cell body staining, but not the punctate inner molecular layer labelling. The rat observations were the same in animals with 0, 24, 48, or 72 h PMI (not shown).
Abundance of sema3A in schizophrenia Sema3A immunoreactivity was significantly increased in schizophrenia compared with controls, having covaried for age, pH and, PMI (F ¼ 4.3, df ¼ 1,30, Po0.05; Figure 3a) . The increase was 45% in densitometric units. A similar change ( þ 37%) was seen when sema3A immunoreactivity was measured in terms of the areal fraction of labelled tissue (not shown). The ELISA confirmed that sema3A was increased in the schizophrenia group ( þ 28%; F ¼ 13.0, df ¼ 1,30, Po0.01; Figure 3b ).
After partialling for diagnosis, sema3A immunoreactivity correlated with age (R ¼ 0.480, df ¼ 29, P ¼ 0.006), but not significantly with pH (R ¼ À0.285, df ¼ 29, P ¼ 0.12) or PMI (R ¼ 0.39, df ¼ 29, P ¼ 0.066). There were no correlations between sema3A and gender, age at onset, duration of illness, clinical subtype, or phase of illness at death (not shown).
Cerebellar reelin mRNA in schizophrenia Reelin mRNA was concentrated over the granule cell layer, with no significant labelling of other cell types. Negligible signal was seen with the ribonuclease pretreated sections or with the sense probe (data not shown). Reelin mRNA signal was 26% lower in schizophrenia (15417164 nCi/g; n ¼ 16) than in controls (2093 þ 131 nCi/g; n ¼ 17). This was not significant by ANOVA with age, pH, and PMI as covariates (F ¼ 3.521, df ¼ 1,32, P ¼ 0.071). Partialling for diagnosis, reelin mRNA declined with brain pH (R ¼ 0.605, df ¼ 30, Po0.001) but was not significantly correlated with age (R ¼ À0.277, df ¼ 30, P ¼ 0.120) or PMI (R ¼ À0.280, df ¼ 30, P ¼ 0.125). Gender and freezer storage time had no effect on reelin mRNA.
Correlations of sema3A with expression of presynaptic markers and reelin Within the molecular layer, many of the synapses are those formed between granule cell axons (parallel fibres) and Purkinje cell dendrites. As sema3A is inhibitory for axonal growth, an inverse relation might be predicted between sema3A and indices of granule cell synaptic markers, and with reelin mRNA which is expressed by these cells and secreted from the parallel fibres. 34 To test this possibility, we correlated sema3A immunoreactivity with the abundance of reelin mRNA and of two synaptic protein mRNAs, synaptophysin and complexin II, shown previously to be decreased in the schizophrenia group studied here. 24 As shown in Figure 4a , there was a significant negative correlation between reelin mRNA and sema3A, similar in both control and schizophrenia groups. Complexin II mRNA was also negatively correlated with sema3A (Figure 4b) , with a trend for synaptophysin mRNA (Figure 4c ).
Discussion
The main findings of the present study are that (1) sema3A is expressed in the adult human cerebellum, with a different localization from that seen in the rat or infant human; (2) cerebellar sema3A is increased in schizophrenia, as determined by ELISA and immunohistochemistry, and (3) sema3A is inversely related to reelin and synaptic protein mRNAs, suggesting that the elevated sema3A, perhaps in combination with the decline in reelin expression, may contribute to the synaptic pathology of the disorder.
Detection and localization of sema3A in human cerebellum Our Western blot, ELISA and immunohistochemical results together show that sema3A, like its mRNA, 22 is present in the adult human cerebellum. Two points merit some consideration before proceeding to the schizophrenia data.
Molecular weights for sema3A ranging from 125 to 33 kDa have been predicted or empirically demonstrated in various cell lines and tissue homogenates. The heterogeneity is because a combination of proteolytic processing of pro-sema3A and dimerization of sema3A cleavage products. 35, 36 Our Western blots of unfractionated protein showed a band of 50 kDa in fetal whole brain (Figure 1b ) and 40 kDa in adult cerebellum (Figure 1a) , consistent with results seen using a similar carboxy-terminal antibody in HEK293 cells and mouse embryo, respectively. 35, 36 The fact that we did not see any clear bands at 125, 95, or 65 kDa, as also reported in some circumstances by these authors, may reflect intrinsically low levels of these sema3A species in human cerebellum, or their susceptibility to perimortem degradation. The change in molecular weight between infants and adults may represent a maturational shift in sema3A processing, and be related to the corresponding alteration in sema3A immunoreactivity from being primarily in Purkinje cell bodies (Figure 2b ) to the adjacent neuropil (Figure 2a) .
With regard to the distribution of sema3A immunoreactivity, its presence in Purkinje cells but not other cell types is in agreement with restriction of sema3A mRNA to Purkinje cells in the adult cerebellum. 22, 37 We interpret the punctate neuropil staining seen in the adults as reflecting the secretion of sema3A into the extracellular matrix. Given the sema3A cellular expression pattern, this seems most likely to be from the proximal dendrites of the Purkinje cells, though it might also arise from axons of neurons situated outside the cerebellar cortex (eg in the inferior olive). Interestingly, reelin shows a somewhat similar immunohistochemical appearance suggestive of secretion by axons and/or dendrites in the neuropil of mouse embryonic cortex, 38 and in the cerebellum it is known to be present in, and presumably secreted from, granule cell axons. 34 Further studies are needed to confirm the source and location of human cerebellar sema3A; we were limited by the morphological quality of the frozen sections and our failure to get reliable immunostaining in formalin-fixed material. Despite these uncertainties, the immunohistochemical distribution of sema3A seen in the adults cannot reasonably be attributed to an artefact of PMI or pH, since it was neither seen in the infant post-mortem tissue ( Figure  2b ) nor in rat brains with simulated PMIs of up to 72 h (Figure 2c ), nor did sema3A immunoreactivity or ELISA signal correlate with PMI in the main series.
Increased sema3A and the neurodevelopmental model of schizophrenia Cerebellar sema3A was increased in schizophrenia, as measured by immunohistochemistry and ELISA (Figure 3 ). Since all patients had received antipsychotics, medication could have caused the sema3A increase, or ameliorated it. We did not examine for correlations between sema3A and drug history since this was incompletely documented, and the available information indicated a relatively narrow range of lifetime drug exposures; together these factors would undermine attempts to identify or exclude significant correlations. Nevertheless, neither the cerebellum nor sema3A seem likely targets of antipsychotics, since most of their neurochemical and morphological sequelae occur in the striatum and prefrontal cortex; 39 moreover, antipsychotics do not alter cerebellar expression of reelin 30 or synaptic proteins. 40 Hence the following discussion assumes that the results relate, in some way, to schizophrenia.
As the established roles for sema3A are primarily in early brain maturation, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] its elevation in schizophrenia may be viewed as supportive of the hypothesized early developmental abnormality underlying the disorder. 4 Though this is an appealing interpretation which may well be true, there is an inherent limitation which tempers such speculation: the fact that sema3A, or any other 'developmental gene', is expressed in adulthood suggests that it has a role after development per se has finished. For semaphorins, including sema3A, later roles in neural plasticity and regeneration are described, which may or may not be a continuation of earlier functions. [41] [42] [43] The same applies to reelin 25 and to other genes such as growthassociated protein-43, [44] [45] [46] nerve cell adhesion molecule, [47] [48] [49] glycogen synthase kinase-3, 50 and Wnt, 51 all of which have both developmental and later roles, and the expression of which is altered in schizophrenia. Instead, the realization that developmental molecules and mechanisms are later involved frequently in neural plasticity, and in neurodegeneration too, 52, 53 means that the dichotomies sometimes implicitly drawn between these processes are misleading and should be avoided. With regard to schizophrenia, it may be argued that a brain which has undergone aberrant neurodevelopment is likely to be impaired in its ability to maintain normal plasticity and perhaps be more vulnerable to degenerative processes, involving the participation of many of the same molecular players. [54] [55] [56] Increased sema3A and synaptic pathology By inhibiting normal, ongoing processes of local axonal growth and plasticity, a persisting elevation of sema3A may contribute to the synaptic pathology of schizophrenia, whenever it originated. Support for this interpretation comes from the inverse correlation between the synaptic protein mRNAs, expressed by granule cells, and sema3A in the molecular layer, where the granule cells form synapses with Purkinje cell dendrites (Figure 4 ), in conjunction with the decreased cerebellar expression of synaptic proteins seen in schizophrenia. 24, 57 This suggests that the local diffusion of sema3A may be acting as a chemorepellant for these synaptic contacts, and perhaps for others in the vicinity. 14, 37 If there is causalty in the inverse correlation between sema3A and synaptic markers, one might predict similar alterations in other brain areas wherein synaptic proteins are decreased in schizophrenia, such as the hippocampal formation and dorsolateral prefrontal cortex. [1] [2] [3] 58 A higher level of the semaphorin effector, collapsin response mediator protein 2, has been reported in the hippocampus in the disorder, 59 providing complementary evidence for an increased activity of the sema3A pathway. Further support may come from investigation of the neuropilins and plexins, which are semaphorin receptors. 60, 61 A relation might also be anticipated between synaptic markers and other gene products involved in axon guidance and pruning, such as ephrins, 62 cadherins, 63 and Otx1. 64 Overall, we assume that sema3A is but one component of a complex set of related gene expression alterations occurring in subjects with schizophrenia across the life span, which together ultimately represent the molecular neuropathology of the disorder. The sequencing of the genome and the advent of large-scale expression arrays and proteomics together allow this fundamental issue to begin to be addressed systematically.
Cerebellar reelin mRNA in schizophrenia Our ISH data show that, as in the rat, 34 reelin mRNA in the adult human cerebellum is limited to granule cells. Guidotti et al, 30 using RT-PCR in the Stanley Foundation brain series, found a decrease of cerebellar reelin mRNA in schizophrenia (À38%; P ¼ 0.008). Our data basically replicate this finding, with a 26% lower reelin mRNA signal in our schizophrenia group. Although the difference was not significant (P ¼ 0.07) by ANCOVA, it was significant (P ¼ 0.013) by the statistical test (one-way ANOVA) used in the earlier study. The difference in significance may be attributed to the influence of pH, which the ANCOVA controls for. Brain pH also affected sema3A immunoreactivity (present study), as it does other gene products, 65 and should be taken into account in future studies whenever possible. 66 A relationship between sema3A, reelin, and synaptic pathology? In summary, we have found that the axonal chemorepellant protein sema3A is increased in the cerebellum in schizophrenia. The downregulation of reelin expression seen equivocally here, and more clearly in other studies 29, 30, 67 raises the question as to whether sema3A and reelin interact in the pathogenesis of schizophrenia, particularly with regard to its synaptic pathology. Simplistically, the combination of increased sema3A and decreased reelin suggests that the equilibrium between repulsive and attractive processes influencing axonal growth and synaptic plasticity is altered in favour of the former, thereby contributing to the reduction in synaptic markers seen in schizophrenia.
Clearly, any proposal of this kind is highly speculative, in part because causalty cannot be established from post-mortem studies alone. Furthermore, many genes apart from sema3A contribute to the formation and maintenance of synapses in the cerebellum, [68] [69] [70] and these will need to be investigated, along with those involved in reelin signalling, for a fuller picture to emerge. Finally, since synaptic pathology 71 and decreased reelin expression 30, 67 may also occur in bipolar disorder, it will be of interest to establish whether sema3A plays a role in that disorder as well.
